疼痛治疗新药物NaV1.8选择性抑制剂Suzetrigine最新研究进展
The Recent Research Progress on the Novel Drug NaV1.8 Selective Inhibitor Suzutrigine for Pain Treatment
DOI: 10.12677/acm.2025.15102756, PDF,   
作者: 罗 锐, 漆 涛*：成都中医药大学附属医院疼痛科，四川 成都
关键词: Suzetrigine；VX-548；急性疼痛；钠离子通道；Suzetrigine； VX-548； Acute Pain； Sodium Channel
摘要: 目前治疗急性疼痛多使用阿片类药物，但其药物依赖性、药物滥用和不良反应明显，开发安全有效的非阿片类镇痛药仍是目前研究的热点。作为新型治疗疼痛的药物，NaV1.8通道抑制剂Suzetrigine (VX-548)通过选择性抑制电压门控钠离子通道，减少疼痛信号在外周感受器的表达，能有效缓解术后急性疼痛，并可降低对中枢神经系统的不良反应如依赖性和药物滥用。目前Suzetrigine在全球已经开展了一系列临床研究，数据显示其不仅可以缓解术后急性疼痛，且安全性和耐受性良好。本综述将对NaV1.8通道抑制剂Suzetrigine的基本情况、药代动力学研究以及各个研究阶段的临床数据进行总结，为急性疼痛的药物选择提供新思路。
Abstract: Opioids are currently widely used for the treatment of acute pain; however, their associated drug dependence, potential for abuse, and adverse effects are significant. The development of safe and effective non-opioid analgesics remains a research focus. As a novel therapeutic agent for pain management, the NaV1.8 channel inhibitor suzetrigine (VX-548) selectively inhibits voltage-gated sodium channels, thereby reducing the transmission of pain signals from peripheral sensory neurons. It has demonstrated efficacy in alleviating acute postoperative pain while minimizing adverse effects on the central nervous system, such as dependence and abuse potential. A series of global clinical studies have been conducted on Suzetrigine, with data indicating not only effective relief of acute postoperative pain but also a favorable safety and tolerability profile. This review summarizes the fundamental characteristics, pharmacokinetic studies, and clinical data from various research phases of the NaV1.8 channel inhibitor Suzetrigine, offering new perspectives for pharmacological management of acute pain.
文章引用：罗锐, 漆涛. 疼痛治疗新药物NaV1.8选择性抑制剂Suzetrigine最新研究进展[J]. 临床医学进展, 2025, 15(10): 286-291. https://doi.org/10.12677/acm.2025.15102756

参考文献

[1] (2012) Practice Guidelines for Acute Pain Management in the Perioperative Setting: An Updated Report by the American Society of Anesthesiologists Task Force on Acute Pain Management. Anesthesiology, 116, 248-273. [Google Scholar] [CrossRef] 
[2] Mol, S., Brown, A.V., Kuijper, T.M., Bouwhuis, M.G., de Groot, B., Out, A.J., et al. (2024) Cumulative Incidence of Chronic Pain after Visiting a Dutch Emergency Department with Acute Pain. BMC Anesthesiology, 24, Article No. 460. [Google Scholar] [CrossRef] [PubMed]
[3] Gustavsson, A., Bjorkman, J., Ljungcrantz, C., Rhodin, A., Rivano‐Fischer, M., Sjolund, K.‐F, et al. (2012) Socio‐Economic Burden of Patients with a Diagnosis Related to Chronic Pain—Register Data of 840,000swedish Patients. European Journal of Pain, 16, 289-299. [Google Scholar] [CrossRef] [PubMed]
[4] Kehlet, H., Jensen, T.S. and Woolf, C.J. (2006) Persistent Postsurgical Pain: Risk Factors and Prevention. The Lancet, 367, 1618-1625. [Google Scholar] [CrossRef] [PubMed]
[5] Stringfellow, E.J., Lim, T.Y., Humphreys, K., DiGennaro, C., Stafford, C., Beaulieu, E., et al. (2022) Reducing Opioid Use Disorder and Overdose Deaths in the United States: A Dynamic Modeling Analysis. Science Advances, 8, eabm8147. [Google Scholar] [CrossRef] [PubMed]
[6] Oliver, B., Devitt, C., Park, G., Razak, A., Liu, S.M. and Bergese, S.D. (2024) Drugs in Development to Manage Acute Pain. Drugs, 85, 11-19. [Google Scholar] [CrossRef] [PubMed]
[7] Jones, J., Correll, D.J., Lechner, S.M., Jazic, I., Miao, X., Shaw, D., et al. (2023) Selective Inhibition of Nav1.8 with VX-548 for Acute Pain. New England Journal of Medicine, 389, 393-405. [Google Scholar] [CrossRef] [PubMed]
[8] Bennett, D.L., Clark, A.J., Huang, J., Waxman, S.G. and Dib-Hajj, S.D. (2019) The Role of Voltage-Gated Sodium Channels in Pain Signaling. Physiological Reviews, 99, 1079-1151. [Google Scholar] [CrossRef] [PubMed]
[9] Facer, P., Punjabi, P.P., Abrari, A., Kaba, R.A., Severs, N.J., Chambers, J., et al. (2011) Localisation of SCN10A Gene Product Nav1.8 and Novel Pain-Related Ion Channels in Human Heart. International Heart Journal, 52, 146-152. [Google Scholar] [CrossRef] [PubMed]
[10] Hameed, S. (2019) Nav1.7 and Nav1.8: Role in the Pathophysiology of Pain. Molecular Pain, 15, 1-11. [Google Scholar] [CrossRef] [PubMed]
[11] 刘怡, 孙娇丽, 李宁波, 等. Nav1.8在足底切口痛模型大鼠背根神经节中表达的研究[J]. 中国疼痛医学杂志, 2019, 25(3): 172-176.
[12] Faber, C.G., Lauria, G., Merkies, I.S.J., Cheng, X., Han, C., Ahn, H., et al. (2012) Gain-of-Function Nav1.8 Mutations in Painful Neuropathy. Proceedings of the National Academy of Sciences, 109, 19444-19449. [Google Scholar] [CrossRef] [PubMed]
[13] Jarvis, M.F., Honore, P., Shieh, C.-C., et al. (2007) A-803467, a Potent and Selective Nav1.8 Sodium Channel Blocker, Attenuates Neuropathic and Inflammatory Pain in the Rat. Proceedings of the National Academy of Sciences of the United States of America, 104, 8520-8525.
[14] Bagal, S.K., Chapman, M.L., Marron, B.E., Prime, R., Storer, R.I. and Swain, N.A. (2014) Recent Progress in Sodium Channel Modulators for Pain. Bioorganic & Medicinal Chemistry Letters, 24, 3690-3699. [Google Scholar] [CrossRef] [PubMed]
[15] Hijma, H.J., Siebenga, P.S., de Kam, M.L., et al. (2021) A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Pharmacodynamic Effects of VX-150, a Highly Selective Nav1.8 Inhibitor, in Healthy Male Adults. Pain Medications, 22, 1814-1826.
[16] Zhang, H., Chen, Y., Huang, J. and Sun, W. (2024) A Simple and Sensitive Ultra‐High Performance Liquid Chromatography Tandem Mass Spectrometry Method for the Quantitative Analysis of VX‐548 in Monkey Plasma: Method Validation and Application to Pharmacokinetic Study. Biomedical Chromatography, 38, e5907. [Google Scholar] [CrossRef] [PubMed]
[17] Yu, G. and Zhou, X. (2024) Gender Difference in the Pharmacokinetics and Metabolism of VX‐548 in Rats. Biopharmaceutics & Drug Disposition, 45, 107-114. [Google Scholar] [CrossRef] [PubMed]
[18] Osteen, J.D., Immani, S., Tapley, T.L., Indersmitten, T., Hurst, N.W., Healey, T., et al. (2025) Pharmacology and Mechanism of Action of Suzetrigine, a Potent and Selective Nav1.8 Pain Signal Inhibitor for the Treatment of Moderate to Severe Pain. Pain and Therapy, 14, 655-674. [Google Scholar] [CrossRef] [PubMed]
[19] Faouzi, A., Varga, B.R. and Majumdar, S. (2020) Biased Opioid Ligands. Molecules, 25, Article 4257. [Google Scholar] [CrossRef] [PubMed]
[20] McCoun, J., Winkle, P., Solanki, D., Urban, J., Bertoch, T., Oswald, J., et al. (2025) Suzetrigine, a Non-Opioid Nav1.8 Inhibitor with Broad Applicability for Moderate-to-Severe Acute Pain: A Phase 3 Single-Arm Study for Surgical or Non-Surgical Acute Pain. Journal of Pain Research, 18, 1569-1576. [Google Scholar] [CrossRef] [PubMed]
[21] Bertoch, T., D’Aunno, D., McCoun, J., Solanki, D., Taber, L., Urban, J., et al. (2025) Suzetrigine, a Non-Opioid Nav1.8 Inhibitor for Treatment of Moderate-to-Severe Acute Pain: Two Phase 3 Randomized Clinical Trials. Anesthesiology, 142, 1085-1099. [Google Scholar] [CrossRef] [PubMed]

为你推荐